Liquid Biopsies and Imaging in Breast Cancer

Summary

The aim of the study is to show proof of concept for combining multi-parametric MRI with liquid biopsies in addition to conventional clinical and pathologic information, to accurately predict response to neoadjuvant treatment for patients with primary breast cancer.

Conditions

• Breast Cancer

Interventions

DIAGNOSTIC_TEST

Liquid biopsy

A blood sample containing circulating tumor DNA and circulating tumor cells.

DIAGNOSTIC_TEST

Multi-parametric MRI

Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.

Sponsors & Collaborators

• Horizon 2020 - European Commission

  collaborator OTHER

• Philips Electronics Nederland BV

  collaborator INDUSTRY

• Agena Bioscience GmbH

  collaborator UNKNOWN

• DiaDx

  collaborator UNKNOWN

• Stilla Technologies

  collaborator UNKNOWN

• ANGLE Europe Limited

  collaborator UNKNOWN

• ALS Automated Lab Solutions GmbH

  collaborator UNKNOWN

• Institut National de la Santé Et de la Recherche Médicale, France

  collaborator OTHER_GOV

• Philips GmbH Innovate Technologies

  collaborator UNKNOWN

• Institut du Cancer de Montpellier - Val d'Aurelle

  collaborator OTHER

• UMC Utrecht

  lead OTHER

Principal Investigators

• Kenneth GA Gilhuijs, PhD · UMC Utrecht

Study Design

Allocation

NA

Purpose

OTHER

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-01-02

Primary Completion

2022-05-16

Completion

2022-05-16

Countries

• Netherlands

Study Locations